share_log

微創醫療：預料上海微創心脈醫療科技（集團）股份有限公司於截至二零二三年十二月三十一日止年度利潤增長

MICROPORT: EXPECTED INCREASE IN PROFIT FOR SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 29 08:00
Summary by Moomoo AI
微創醫療科學有限公司（「微創醫療」）於2024年1月29日宣布，其持股40.32%的上海微創心脈醫療科技（「心脈醫療科技」）預計於2023年度實現顯著利潤增長。心脈醫療科技的營業收入預計達到人民幣117,441.55萬元至120,131.05萬元，年增長率介於31%至34%。淨利潤預計達到人民幣47,464.84萬元至49,249.23萬元，年增長率為33%至38%。扣除非經常性損益後的淨利潤預計增長33%至40%。2023年，心脈醫療科技的產品銷售和終端植入量持續快速增長，新產品如Talos®和Fontus®系統在超過300家醫院使用，並有超過3200例植入。此外，心脈醫療科技在海外市場的銷售收入同比增長超過50%，多款產品已在全球多國進入臨床應用。公司表示，隨著新產品推廣力度加大，預期2024年新品植入量及銷售額將持續增長。投資者應注意，上述財務資料未經審核，並僅與心脈醫療科技業務相關，不代表微創醫療整體業務狀況。
微創醫療科學有限公司（「微創醫療」）於2024年1月29日宣布，其持股40.32%的上海微創心脈醫療科技（「心脈醫療科技」）預計於2023年度實現顯著利潤增長。心脈醫療科技的營業收入預計達到人民幣117,441.55萬元至120,131.05萬元，年增長率介於31%至34%。淨利潤預計達到人民幣47,464.84萬元至49,249.23萬元，年增長率為33%至38%。扣除非經常性損益後的淨利潤預計增長33%至40%。2023年，心脈醫療科技的產品銷售和終端植入量持續快速增長，新產品如Talos®和Fontus®系統在超過300家醫院使用，並有超過3200例植入。此外，心脈醫療科技在海外市場的銷售收入同比增長超過50%，多款產品已在全球多國進入臨床應用。公司表示，隨著新產品推廣力度加大，預期2024年新品植入量及銷售額將持續增長。投資者應注意，上述財務資料未經審核，並僅與心脈醫療科技業務相關，不代表微創醫療整體業務狀況。
Micro-Chung Medical Sciences Co., Ltd. (“Micro-Chung Medical”) announced on 29 January 2024 that its holding of 40.32% of Shanghai Micro-Chung Cardiac Medical Technology (“Cardiac Medical Technology”) is expected to achieve significant profit growth in 2023. Cardiac Medical Technology's revenue is expected to reach RMB117,441.55 million to RMB120,131.05 million, with year-on-year growth of 31% to 34%. Net profit is expected to reach RMB 47,464.84 million to RMB 49,249.23 million, with a year-on-year growth rate of 33% to 38%. NET PROFIT AFTER NON-RECURRING LOSSES IS EXPECTED TO GROW 33% TO 40%. Cardiac Medical Technology's product sales and terminal implantation volumes continue to grow rapidly in 2023, with new products such as Talos® and Fontus® systems being used in more than 300 hospitals and more than 3200 implants. In addition...Show More
Micro-Chung Medical Sciences Co., Ltd. (“Micro-Chung Medical”) announced on 29 January 2024 that its holding of 40.32% of Shanghai Micro-Chung Cardiac Medical Technology (“Cardiac Medical Technology”) is expected to achieve significant profit growth in 2023. Cardiac Medical Technology's revenue is expected to reach RMB117,441.55 million to RMB120,131.05 million, with year-on-year growth of 31% to 34%. Net profit is expected to reach RMB 47,464.84 million to RMB 49,249.23 million, with a year-on-year growth rate of 33% to 38%. NET PROFIT AFTER NON-RECURRING LOSSES IS EXPECTED TO GROW 33% TO 40%. Cardiac Medical Technology's product sales and terminal implantation volumes continue to grow rapidly in 2023, with new products such as Talos® and Fontus® systems being used in more than 300 hospitals and more than 3200 implants. In addition, Cardiac Medical Technology's sales revenue in overseas markets grew by more than 50% year-on-year, and many products have entered clinical applications in multiple countries around the world. The company said it expects continued growth in new product shipments and sales in 2024 as new product promotion efforts increase. Investors should note that the above financial information is unaudited and relates only to the Cardiac Medical Technology business and does not represent the overall performance of Micro Medical.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more